How is the treatment duration determined for Dacomitinib (Dacomitinib)?

Dacomitinib (Dacomitinib), as a targeted therapy drug for EGFR mutation-positive non-small cell lung cancer (NSCLC), its dosage period is not fixed, but needs to be flexibly adjusted according to the patient's individual condition and treatment effect

Typically, dacomitinib is used as a first-line treatment option for patients with NSCLC. During treatment, patients continue to take the drug until their disease progresses or they become unable to tolerate the side effects. Due to individual differences and different treatment responses, the duration of medication for each patient will also vary, and some patients may even benefit from the therapeutic effects of dacomitinib (dacomitinib) in the long term.

During treatment, doctors will regularly monitor the patient's tumor response and disease progression through imaging examinations (such as CT scans or MRI) and clinical evaluations to determine whether dacomitinib (dacomitinib) is still able to effectively inhibit tumor growth.

However, similar to many targeted therapies,Dacomitinib may also face resistance problems after a period of treatment, including primary resistance and acquired resistance. The emergence of drug resistance may affect the therapeutic effect of the drug, leading to disease progression or the need to change other treatment options.

Once a patient develops disease progression or drug resistance, doctors may consider adjusting treatment strategies, such as switching to other targeted drugs (such as osimertinib for theT790M mutation), chemotherapy drugs, or participating in new treatments in clinical trials.

In general, the dosage cycle of dacomitinib is highly individualized and is affected by multiple factors such as patient disease characteristics, risk of drug resistance, treatment response and personal health status. Therefore, patients and doctors need to discuss and formulate an appropriate treatment plan together in order to maximize the treatment effect while protecting the patient's quality of life.